Stocks often trade at low prices for specific reasons, such as underlying issues within the company or the market’s failure to recognize their true potential. For instance, stocks trading under $15 may face challenges in business operations, struggle with profitability, or have difficulty managing growth. That’s why some people are averse to investing in these stocks.
However, despite these potential hurdles, investors can occasionally uncover hidden gems with solid long-term prospects and strong analyst support. By carefully analyzing these stocks, you might discover one with significant growth potential over the next few years.
In this article, I have screened the market to identify under-$15 stocks that present a compelling growth case. I used the following screening criteria to compile my list:
- Trading price: Below $15,
- Analyst coverage: 12 or more analysts,
- Analyst rating: “Strong buy,”
- Earnings growth: Positive based on the latest fiscal year,
- Revenue growth: 10% or more based on the latest fiscal year.
I then sorted the list by the highest earnings growth and selected the top three. This allows me to focus on stocks that have shown strong financial improvements and have a solid following from Wall Street experts due to their growth potential.
Here, then, are the results for the best stocks under $15 to buy:
Carnival Corp (CCL)
Carnival Corporation (NYSE:CCL), the world’s largest leisure travel company, operates a portfolio of cruise lines, including Costa Cruises, Carnival Cruise Line, Holland America Line, and more. The company’s business is divided into several segments:
- North America and Australia (NAA): Operates cruise lines such as Seabourn and Carnival Cruise Line,
- Europe: Operates AIDA Cruises (AIDA), P&O Cruises (UK), and others,
- Cruise Support: Manages port destinations and other services,
- Tour and Others: Oversees the company’s lodges, hotels, and various non-cruise services.
As the travel and leisure industry recovers, Carnival capitalizes on the influx of passengers by offering additional Antarctica sailings through 2026, allowing travelers to explore the great white continent.
It’s no surprise that Wall Street maintains a strong buy consensus recommendation for Carnival Corp. The company ended FY 2023 with a 77.46% year-over-year (YOY) revenue growth, reaching $21.59 billion, up from $12.17 billion last year. Its bottom line also saw a significant 98.84% YOY increase, moving from a loss of $5.16 per share to just a $0.06 loss per share.
The latest Q2 results indicate a promising 2024, with earnings showing a seven-cent profit and revenue reaching $5.8 billion. Carnival has also upgraded its outlook for the year, raising its net income forecast by $275 million and projecting adjusted EBITDA to reach $5.83 billion, representing a 40% YOY growth. With a strong market outlook, solid performance, and a current stock price below $15, CCL is a strong contender for investors seeking substantial portfolio gains.
Grab Holdings Limited (GRAB)
Known for its strong presence in Southeast Asian markets, Grab Holdings Limited (NASDAQ:GRAB) initially started as a taxi-hailing app and has since evolved into the super app we know today. The company’s app now offers various services, including food deliveries and digital financial services.
Recently, Grab announced a partnership with OpenAI to enhance the customer experience by developing AI tools for its users and partners. This collaboration aims to improve mapping, accessibility, and customer support through advanced AI technologies.
Grab Holdings has been on a robust growth trajectory in recent fiscal years, continuing to dominate the Asian market. In FY2023, revenue surged by 64.62% year-over-year (YOY), reaching $2.36 billion, up from $1.43 billion. Earnings also saw a significant improvement, with a 75% YOY increase, narrowing the loss from $0.44 to $0.11 per share. The company’s momentum continued into Q1 2024, with a 24% YOY revenue increase, adjusted EBITDA hitting an all-time high of $62 million, and an 18% YOY growth in its on-demand gross merchandise value (GMV).
Grab has also raised its 2024 adjusted EBITDA guidance to $250-$270 million, up from the original estimate of $180-$200 million. With this strong growth performance, a strong buy consensus from analysts, and an attractive stock price below $5, GRAB presents a compelling case for multi-bagger potential by 2027.
Taysha Gene Therapies (TSHA)
Taysha Gene Therapies (NASDAQ:TSHA) is a clinical-stage biotech company specializing in adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system diseases. The company’s lead clinical program, TSHA-102, is focused on Rett syndrome and is currently being evaluated in the REVEAL Phase I/II clinical trials. Additionally, Taysha holds the rights to the AAV9 gene therapy program, TSHA-120, which targets giant axonal neuropathy (GAN).
Recent updates from Taysha indicate promising progress in their gene therapy trials for Rett syndrome, with encouraging results from TSHA-102. The trials have shown no serious adverse events or dose-limiting toxicities at higher doses in adolescent and adult trials. Data from the earlier cohort of these trials is expected to be released in the second half of 2025, signaling substantial growth potential.
On the financial side, Taysha’s FY 2023 results showed significant improvement, with a net loss of $0.96 per share—a 74.60% year-over-year improvement. The company also achieved a remarkable 518% year-over-year revenue growth, reaching $15.45 million. Wall Street analysts have a strong buy consensus recommendation for Taysha, underscoring its growth potential. With a low-cost entry point of around $2, TSHA is a stock worth considering for those seeking significant gain potential.
Disclaimers:
On the date of publication, Rick Orford did not have any positions in the companies published in this article.
Investment Risk Disclaimer
Making decisions to buy, sell, hold, or trade securities, commodities, or other financial investments carries inherent risks. These decisions are best made with the guidance of a qualified financial professional. Trading in securities or other financial assets can lead to significant losses. The practice of “day trading” is particularly risky and can result in substantial financial loss. Before starting any trading strategy, it’s crucial to consult with a qualified financial advisor to determine if it aligns with your financial situation and risk tolerance. RickOrford.com is not liable for any losses or damages incurred from trading or investment activities based on information or materials obtained through this site.
No Financial Advice or Solicitation
The content on RickOrford.com is not intended to offer tax, legal, or investment advice and should not be interpreted as a solicitation to buy or sell securities.
